News | Atrial Fibrillation | May 15, 2018

First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI

Unique aspect of the study is its use of a new smartphone app used to capture data from physicians and patients

First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and objective assessment of stroke, stent thrombosis and bleeding risk in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). The data was presented as late-breaking clinical science at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

The AVIATOR 2 is a multicenter prospective observational study of AF patients undergoing PCI in 11 international sites.[1] The use of a novel smartphone-based survey was used to capture physician and patient perspectives regarding antithrombotic therapies (ATT) after PCI.

AF is one of the most common abnormal heart arrhythmias that affects more than 2.7 million adults in the United States.[2] PCI is a nonsurgical procedure that improves blood flow to the heart by using a stent to open up blood vessels. Patients with AF undergoing PCI present a particular challenge for ATT selection. Finding the right balance that minimizes bleeding risk and maintains anti-ischemic efficacy remains a complex situation in these unique patients. In the era of novel antithrombotic therapy, the optimal ATT for patients with AF undergoing PCI is undetermined.

The choice of ATT was made by the physician. After PCI, physicians were asked to complete a survey to rate subjective stroke, ischemic risk and bleeding risk in patients. The survey was completed via a smartphone app called AVIATOR, which was developed at the Icahn School of Medicine at Mount Sinai. The calculated risk scores, including CHA2DS2, VASc, ST and HASBLED, were compared against physician rated risks.

A total of 515 patients with AF undergoing PCI were enrolled with a mean age of 73±10 years including 25.8 percent females. Safety (93.8 percent) and efficacy (89.9 percent) were the top two factors physicians reported as the most important factors when making the medication selection. In less than half (49.1 percent) of patients, the physician assessment showed an underestimation of risk in 26.9 percent and overestimation in 22.2 percent of patients when compared to the CHA2DS2VASc score. Physician assessment showed an overestimation of ischemic risk for ST in 71.5 percent and an underestimation in 4.6 percent for calculated ST scores. Overall, the assessment between the subjective physician assessed and objective risk scores for stroke, ischemic risk and bleeding varied.

“It is the first time we are collecting subjective risk assessment and comparing it with empiric calculations based on baseline characteristics and known risk calculators,” said lead author Roxana Mehran, M.D., director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Icahn School of Medicine at Mount Sinai in New York, N.Y. “It is also the first time we used a smartphone application to gain perspective from both the physicians and the patients. In today’s technological landscape, this type of accessible technology allows for the integration of the patient in decision-making and solidify the notion that patient concerns matter.”

The authors note that longitudinal follow-up will provide further insights on the correlation between risk estimation and cardiovascular events. The study was conducted by physicians from around the world, including Jaya Chandrasekhar, MBBS, MS, Usman Baber, M.D., MS, Melissa Aquino, MS, Birgit Vogel, M.D., Clayton Snyder, BS Samantha Sartori, Ph.D., Annapoorna Kini, M.D., George Dangas, M.D., Ph.D., and Davide Capodanno, M.D.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

References:

1. Chandrasekhar J, Mastoris I, Baber U, et al. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015 Dec;170(6):1234-42. doi: 10.1016/j.ahj.2015.08.023. Epub 2015 Sep 21.

2. Centers for Disease Control and Prevention (CDC). Atrial Fibrillation Fact Sheet. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Accessed April 20, 2018.

Related Content

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

,

Figure 1: The approval of Andexxa was supported by data from two Phase 3 ANNEXA studies (ANNEXA-R and ANNEXA-A), which evaluated the safety and efficacy of the drug in reversing the anticoagulant activity of the factor Xa inhibitors rivaroxaban and apixaban. This chart shows the reversal response for rivaroxaban.

,

Figure 2: The approval of Andexxa was supported by data from two Phase 3 ANNEXA studies (ANNEXA-R and ANNEXA-A), which evaluated the safety and efficacy of the drug in reversing the anticoagulant activity of the factor Xa inhibitors rivaroxaban and apixaban. This chart shows the reversal response for apixaban.

 

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Overlay Init